Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma
Author:
Funder
Sanofi
Baxalta
Daiichi-Sankyo
GlaxoSmithKline
Karyopharm Therapeutics
Novartis
AbbVie
Celgene
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Hematology
Link
http://www.nature.com/articles/s41408-019-0198-4.pdf
Reference29 articles.
1. Lichtman, M. A. Battling the hematological malignancies: the 200 years’ war. Oncologist 13, 126–138 (2008).
2. Plawny, L. & Ries, F. Emerging new anticancer biological therapies in 2013 (haematological malignancies). Curr. Opin. Oncol. 26, 363–370 (2014).
3. Kumar, S. K. et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 111, 2516–2520 (2008).
4. Eshaghian, S. & Berenson, J. R. Multiple myeloma: improved outcomes with new therapeutic approaches. Curr. Opin. Support. Palliat. care 6, 330–336 (2012).
5. Rajkumar, S. V. Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma?. Hematology Am. Soc. Hematol. Educ. Program 2012, 354–361 (2012).
Cited by 84 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Preclinical characterization of a novel investigational monoclonal antibody CM313 with potent CD38-positive cell killing activity;Frontiers in Immunology;2024-05-03
2. Role of regulatory T cells in pathogenesis and therapeutics of autoimmune hemolytic anemia;Regulatory T Cells and Autoimmune Diseases;2024
3. Harnessing the Power of CAR-NK Cells: A Promising Off-the-Shelf Therapeutic Strategy for CD38-Positive Malignancies;IRAN J IMMUNOL;2023
4. A safety review of recently approved and emerging drugs for patients with relapsed or refractory multiple myeloma;Expert Opinion on Drug Safety;2023-11-02
5. Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation;Leukemia;2023-06-14
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3